Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Profound Medical (PROF) EBITDA (2024 - 2025)

Profound Medical has reported EBITDA over the past 2 years, most recently at -$7.9 million for Q4 2025.

  • Quarterly results put EBITDA at -$7.9 million for Q4 2025, down 14.24% from a year ago — trailing twelve months through Dec 2025 was -$40.3 million (down 31.49% YoY), and the annual figure for FY2025 was -$40.3 million, down 31.49%.
  • EBITDA for Q4 2025 was -$7.9 million at Profound Medical, up from -$8.8 million in the prior quarter.
  • Over the last five years, EBITDA for PROF hit a ceiling of -$6.9 million in Q4 2024 and a floor of -$13.0 million in Q2 2025.